Pre-Conference Immune-Disease Focus Day

TUESDAY, JUNE 29 | 8.55 - 16.00 EDT

8:55 am Chairperson’s Opening Remarks

9:00 am Panel Discussion – What do we need to know about the interaction between the microbiome and the immune system?

  • Louis Cohen Assistant Professor, Icahn School of Medicine, Mount Sinai
  • Julia Drewes Assistant Professor of Medicine, John Hopkins Medical Center
  • Christine Spencer Senior Research Scientist, Parker Institute

9.30am Speed Networking Session

Exploring the Microbiome’s Links to Inflammatory Bowel Disease

10:00 am Optimizing Pre-Clinical Models of Intestinal Inflammation to Better Translate Results of Microbiota Manipulation to Clinical Trials

  • R Balfour Sartor Professor, Division of Gastroenterology & Hepatology, UNC Multidisciplinary IBD Center


• There are a broad range of preclinical models, each of which have advantages and disadvantages to guide their usefulness for a particular application. None completely replicates all features of IBD
• Replicating results in 2 or more models, at least one of which is a chronic immune-mediated, with treatment as well as prevention protocols have the best chance to predict clinical outcomes
• Animal models are best used to test proof of concepts and explore mechanisms of action

10:30 am Moving Towards Live Biotherapeutics for Inflammatory Bowel Disease

  • Louis Cohen Assistant Professor, Icahn School of Medicine, Mount Sinai


• Discuss discovery pipeline for live biotherapeutics
• Review early stage live biotherapeutic therapies
• Highlight live biotherapeutic therapies in early stage trials

11:00 am Immunomodulation by the Human Enteric Virome

  • Kate Jefferey Assistant Professor of Medicine, Harvard Medical School


• Bacteria are the headliners of microbiome research, leaving the role of eukaryotic or prokaryotic viruses (collectively, the virome) that also inhabit asymptomatic humans, and fluctuate in disease including IBD, as largely undefined
• How and which constituents of the resident virome contribute to host immune state or how changes in virus composition impacts inflammation is almost completely unknown
• We demonstrate that the human enteric virome is functionally divergent and autonomously drives disease phenotypes. Harnessing the virome may be beneficial in IBD and other diseases

11.30am Networking Lunch

The Microbiome & Immuno-Oncology

12:30 pm The Gut Microbiota “Ecosystem on a Leash” Affects Immune Cell Dynamics in Humans

  • Jonas Schluter Tenure track Assistant Professor , NYU Langone Health, Grossman School of Medicine, Department of Microbiology, Institute for Computational Medicine

1:00 pm Overcoming Resistance to Anti-PD-1 Therapy Through Microbiome Modulation

  • Diwakar Davar Assistant Professor, Melanome & Phase I Therapy, UPMC, Hillman Cancer Center


• Microbiome modulation using responder-derived FMT overcomes primary resistance to anti-PD-1 therapy
• R-FMT results in rapid and durable perturbations in gut microbiota of recipients
• Responders to R-FMT have reduction in intra-tumoral myeloid cells and evidence of adaptive immunity and memory response peripherally

1:30 pm Mechanisms of Colonic Biofilm-Associated Tumorigenesis

  • Julia Drewes Assistant Professor of Medicine, John Hopkins Medical Center


• A subset of colonic biofilms from patients are tumorigenic in mouse models of colon cancer
• IL-17 responses are critical for biofilm-associated tumor induction
• Metabolites may play a role in biofilm-associated tumor induction as well

2:00 pm Going Bold on Cancer Immunotherapy and the Gut Microbiome


• Understanding the latest research looking at the microbiome and cancer immunotherapy
• The gut microbiome & cancer immunotherapy at PICI
• Collaborative work with MD Anderson on cancer immunotherapy, the gut microbiome and host factors

2:30 pm Single Pipeline Re-Analysis Revises Microbiome Associations With Anti-Tumor Response to Checkpoint Inhibitors


• Re-analysis of raw sequencing data through a single high-dimentional pipeline identified novel signals
• Microbial signals associated with non-response showed the strongest correlations
• An integrated index of the novel signals was tested in 3 additional cohorts and validated in two tumour types

3:00 pm Chairperson’s Closing Remarks

3.05pm Afternoon Coffee Rooms

4:00 pm End of Pre-Conference Day